Stockscreener 앱 받기
146.50
122.82%
83.54
전일 마감가:
$62.96
열려 있는:
$116.02
하루 거래량:
114.65M
Relative Volume:
14.06
시가총액:
$57.79B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-17.98
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
+120.33%
1개월 성능:
+126.92%
6개월 성능:
+182.26%
1년 성능:
+402.63%
1일 변동 폭
$114.46
$163.47
1주일 범위
$60.82
$163.47
52주 변동 폭
$22.28
$163.47
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
144.75 | 25.73B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
543.00 | 130.67B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.66 | 82.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,025.70 | 61.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.40 | 45.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna shares soar as mRNA cancer vaccine succeeds in late-stage trial - Proactive financial news
Brookline reiterates Moderna stock rating on positive melanoma data - Investing.com
U.S. Treasury Doubles Long-Term Bond Buybacks; Stocks Open Higher as Moderna Soars Over 80% - finance.biggo.com
Moderna (MRNA) Shares Surge Over 90% After Successful Skin Cance - GuruFocus
Moderna Stock Eyes Best Day Ever After Cancer Vaccine Breakthrough - Schaeffer's Investment Research
MRNA Looks 389.5% Overvalued on GF Value™ After Cancer Trial Sur - GuruFocus
Moderna skyrockets 120% on melanoma treatment - Breakingthenews.net
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - benzinga.com
Moderna takes off, while Trainline and Rockwool under pressure - marketscreener.com
Moderna stock more than doubles on Phase 3 win: Time to take profits? - Investing.com
Moderna Stock Jumps 86% on First mRNA Cancer Trial Win - GuruFocus
Wall St up after tech selloff as yields retreat; Moderna surges - marketscreener.com
Moderna’s Cancer Breakthrough Sends the Stock Soaring 84% - Barron's
Merck jumps by 10% on melanoma vaccine update - Breakingthenews.net
Moderna-Merck melanoma therapy averts cancer recurrence in study - Chicago Tribune
MRNA Looks 159.3% Overvalued on GF Value™ - GuruFocus
Moderna (NASDAQ:MRNA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Moderna stock hits 52-week high at 115.6 USD - Investing.com
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal - BioSpace
Moderna shares jump over 90% after cancer vaccine shows positive Phase 3 results - CNBC TV18
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial - Yahoo Finance
Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market - Barron's
MRNA Gains New Catalyst As FDA Clears mFLUSIVA Flu Shot - timothysykes.com
Healthcare ETFs rally as Moderna nearly doubles on melanoma win - Seeking Alpha
MRNA Looks 159.3% Overvalued on GF Value™ Amid Premarket Surge - GuruFocus
MRNA Looks 159.3% Overvalued on GF Value™ as Price-to-Sales Soars Amid Trial Optimism - GuruFocus
Moderna, Inc. stock Analysis: Daily Bullish Trend and Key Catalyst - The Cryptonomist
Merck & Company, Inc. stock Analysis: Daily Trend & Vaccine Impact - The Cryptonomist
William Blair Upgrades Moderna to Outperform From Market Perform - marketscreener.com
Moderna (NASDAQ:MRNA) Stock Rating Upgraded by William Blair - MarketBeat
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial - Yahoo! Finance Canada
Wall St set for higher open after retail earnings; Moderna soars - Yahoo Finance
Moderna's mRNA Vaccine Trial Success Boosts Stock (MRNA) - GuruFocus
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data - Investopedia
Moderna’s stock doubles on promising cancer-vaccine results - MarketWatch
Why is Moderna stock surging today? By Investing.com - Investing.com South Africa
Moderna Surges Over 100% Pre-Market as Phase 3 Cancer Vaccine Trial With Merck Succeeds - TradingKey
Moderna Shares Skyrocket 85% Toward Best Day Ever—On Success Of Cancer Drug Trial - Yahoo Finance UK
MRNA Stock Jumps As FDA Clears New Flu Vaccine - StocksToTrade
Why Moderna stock is rocketing today - Finbold
Moderna (MRNA) and Merck Achieve Milestone with Personalized Can - GuruFocus
Moderna shares soar after major cancer vaccine breakthrough - NBC Boston
Moderna's personalized cancer vaccine shows success in Phase 3 trial - The Business Journals
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
First Look: Meta Faces Trial, Target Surges, Moderna Cancer Vacc - GuruFocus
Moderna shares soar over 100% on melanoma drug trial success - Investing.com
Moderna Stock Jumps 57% as Cancer-Vaccine Win Clears Every Analyst Target - TechStock²
MRNA Stock Eyes Next Leg As FDA Clears New Flu Shot - StocksToTrade
MRNA Jumps As FDA Clears mFLUSIVA Flu Vaccine - timothysykes.com
Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar - benzinga.com
Moderna jumps premarket after Phase 3 trial, Target slides By Investing.com - Investing.com Nigeria
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.12%
0.94%
자본화:
|
볼륨(24시간):